| Identification | Back Directory | [Name]
Tauro--muricholic Acid (sodium salt) | [CAS]
145022-92-0 | [Synonyms]
T-βMCA sodium
Tauro-β-muricholic acid sodium
Tauro-β-muricholic Acid sodium salt | [Molecular Formula]
C26H44NO7S*Na | [MOL File]
145022-92-0.mol | [Molecular Weight]
539.7 |
| Chemical Properties | Back Directory | [Melting point ]
120-125oC | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly), Water (Slightly) | [form ]
Solid | [color ]
White to Pale Beige | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Description]
Tauro-β-muricholic acid (TβMCA) is a competitive and reversible antagonist of the farnesoid X receptor (FXR; IC50 = 40 μM) and a taurine-conjugated form of the murine-specific primary bile acid β-muricholic acid . TβMCA accumulates in germ-free mice under normal conditions but is reduced after colonization with feces from a human donor. TβMCA is increased in the intestines of mice resistant to high-fat diet-induced obesity, fatty liver, and diabetes. | [Uses]
Tauro-β-muricholic Acid Sodium Salt is the salt form of Tauro-α-muricholic Acid which is a bile acid released by the liver and is typically used in cholestasis studies. | [in vivo]
T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression[3].
T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17[3].
| Animal Model: | APCmin/+ mice[3] | | Dosage: | 400 mg/kg | | Administration: | Oral gavage; twice a week; for 6 weeks | | Result: | Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|